 |
Strong Buy (4.00 out of 4)
100th percentile
|
|
|
 Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Thursday, April 18, 1:21 PM
Slide #103. VistaGen Therapeutics, Inc. — Preferred Stock Offering
| Company: |
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) |
| Date announced: |
12/17/2020 |
| Shares Offered: |
2,000,000 |
| Date of Pricing: |
12/18/2020 |
| Price Per Share: |
$21.16 |
| Preferred Stock Offering Details: |
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that it commenced an underwritten public offering of units consisting of its common stock, par value $0.001 per share (the "Common Stock"), and its Series D convertible preferred stock (the "Series D Preferred Stock"). All securities to be sold in the offering are to be sold by VistaGen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 12/18- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the "Common Stock"), and 2,000,000 shares of its Series D convertible preferred stock ("Series D Preferred Stock") at a public offering price of $21.16 per share. |
Vistagen Therapeutics is a late clinical-stage biopharmaceutical company engaging in the treatment for individuals living with anxiety, depression and other central nervous system disorders. Co.'s product candidates include: fasedienol (PH94B), which is used for treatment of social anxiety disorder; Itruvone (PH10), which is used for depression disorders; PH80, which is used for treatment of both vasomotor symptoms (hot flashes) due to menopause and migraine headaches; PH15, which is used for treatment to improve cognitive impairment caused by mental fatigue and other disorders; and AV-101, which is an oral prodrug that targets the N-methyl-D-aspartate receptor.
 Open the VTGN Page at Preferred Stock Channel »
Open the VTGN Page at Preferred Stock Channel (in a new window) »
|
|
Free VTGN Email Alerts:
